clinical trial · NCT01954992
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
Metastatic Pancreatic AdenocarcinomaGlufosfamideFluorouracil
brief summary
The study is designed to assess whether glufosfamide provides additional survival benefit as compared to bolus 5-FU in patients with metastatic pancreatic cancer who have already progressed or failed therapy on a gemcitabine based first line regimen.
started
Apr 1, 2014
primary completion
Jun 1, 2026
completion
Dec 1, 2026
last updated
Dec 31, 2024
official title
A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Fluorouracil (5-FU) in Patients With Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol